Dr. Liu has multiple years of experience in licensing & business development, market development, and biomedical research. He was on the Executive Committee of Sino-American Pharmaceutical Professionals Association (SAPA) from 2004 to 2010. From 2016 to June 2020, Dr. Liu was Senior Vice President of Global Corporate Development at Alphamab, a leading innovative biotech company in China. He was primarily responsible for global business development initiatives and closed multiple deals licensing, research collaboration and strategic partnership. From 2011 to May 2016, Dr. Liu was Head of Global Business Development at Hengrui Pharmaceuticals. At Hengrui, he closed dozens of licensing and partnership agreements with leading multi-national and Chinese companies, such as the $795-million out-licensing deal with Incyte for PD-1 mAb and in-licensing of Rolapitant from Tesaro. Prior to Hengrui, Dr. Liu held increasing responsibilities for global commercial development at Alexion Pharmaceuticals and licensing & business development at Purdue Pharma L.P., a leading private pharmaceutical company in the U.S. He closed multiple deals in commercialization partnering, product acquisition, licensing, and research alliance.

Dr. Liu obtained his bachelor degree in biochemistry at Nanjing University, Ph.D. degree in cancer biology at Eppley Cancer Institute in the US, and MBA degree at Washington University in St. Louis. In his earlier academic career, Dr. Liu conducted translational medical research at Yale University School of Medicine